Stock Monitor: BioLine Rx Post Earnings Reporting
LONDON, UK / ACCESSWIRE / March 27, 2018 / Active-Investors.com has just released a free research report on vTv Therapeutics Inc. (NASDAQ: VTVT). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/'symbol=VTVT as the Company's latest news hit the wire. On March 23, 2018, the Company announced that it has completed Phase-1b part of Simplici-T1, an adaptive Phase-1b/2 clinical trial assessing the pharmacokinetics, pharmacodynamics, safety and tolerability of TTP399 in adult patients with type 1 diabetes (T1D). The study is designed to evaluate TTP399 as an add-on to insulin therapy for T1D. Register today and get access to over 1,000 Free Research Reports by joining our site below:
www.active-investors.com/registration-sg
Active-Investors.com is currently working on the research report for BioLine Rx Ltd (NASDAQ: BLRX), which also belongs to the Healthcare sector as the Company vTv Therapeutics. Do not miss out and become a member today for free to access this upcoming report at:
www.active-investors.com/registration-sg/'symbol=BLRX
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, vTv Therapeutics most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
www.active-investors.com/registration-sg/'symbol=VTVT
TTP399 was Found to be Well-Tolerated in Phase-1b Assessment
The Phase-1b assessment was an open label dose-escalation study in five patients with T1D, designed to determine the tolerability of TTP399 when added to insulin and the appropriate dosing range to be used in Phase-2 of the study. Results showed that TTP399 was found to be well-tolerated and improved or maintained glycemic control while reducing or simplifying an insulin regimen.
TTP399 Demonstrated Significant Reduction in HbA1c Levels in Phase-2b Trial for Type-2 Diabetes
In August 2016, vTv Therapeutics reported positive top-line results from a placebo and active-comparator-controlled Phase-2b clinical study of TTP399 for the treatment of Type-2 diabetes. In the six-month clinical trial, TTP399 demonstrated a statistically significant reduction in HbA1c levels in all TTP399 dose groups compared with placebo. TTP399 was also found to be well-tolerated without increased incidences of hypoglycemia and hyperlipidemia compared to placebo. In type-2 diabetes, the pancreas still makes insulin, but the cells cannot use it very efficiently.
vTv Therapeutics to Initiate Phase-2 Portion of the Simplici-T1 Study in April 2018
Carmen Valcarce, Ph.D., Executive Vice President and Chief Scientific Officer at vTv Therapeutics, stated that the Company is pleased that TTP399 continues to show favorable tolerability and hope that further exploration of the therapy in T1D will produce the same positive effects that were evident in previous type-2 diabetes clinical studies. Carmen added that the Company will initiate the Phase-2 portion of the Simplici-T1 study in April of this year and to further assess the potential of TTP399 as an insulin-adjunctive therapy for T1D to provide superior glucose control than insulin monotherapy.
About Type-1 Diabetes
T1D is a chronic condition in which the pancreas produces little or no insulin. Insulin is a hormone needed to allow sugar (glucose) to enter cells to produce energy. Different factors, including genetics and some viruses, may contribute to T1D. Although T1D usually appears during childhood or adolescence, it can develop in adults. T1D signs and symptoms can appear relatively suddenly and may include increased thirst, frequent urination, bed-wetting in children, extreme hunger, unintended weight loss, irritability, fatigue and weakness, and blurred vision.
About TTP399
TTP399 is an orally available glucokinase enzyme (GK) activator that is designed for superior glucose control by targeting GK activation only in the liver. TTP399 exhibits an insulin-independent mechanism of action which may be suitable as an adjunctive treatment for T1D. The glucokinase enzyme (GK) is a key regulator of glucose metabolism, and its activation has been shown to increase glucose utilization, which in turn lowers blood glucose.
About vTv Therapeutics Inc.
Headquartered in High Point, North Carolina, vTv Therapeutics is a clinical-stage pharmaceutical company focused on the discovery and development of human therapeutics to fill unmet medical needs. The Company has a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, diabetes and metabolic disorders, inflammation and cancer.
Stock Performance Snapshot
March 26, 2018 - At Monday's closing bell, vTv Therapeutics' stock dropped 2.05%, ending the trading session at $4.29.
Volume traded for the day: 117.15 thousand shares.
After yesterday's close, vTv Therapeutics' market cap was at $154.57 million.
The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 1.9% at the end of the session.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
